Comment from International Pemphigus and Pemphigoid Foundation

Summary: The International Pemphigus and Pemphigoid Foundation (IPPF) supports the Haystack Project’s Petition for Rulemaking to modernize FDA regulatory processes for rare autoimmune blistering diseases. They argue that current clinical trial endpoints and study designs are poorly suited to the clinical reality of pemphigus and pemphigoid, and they advocate for disease-specific, patient-centric, and pragmatic trial frameworks.